Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Deadline Approaching: Apply for the Fierce AI Innovation Awards Biotech SPOTLIGHT: Teva takes control of Azilect By admin Jul 11, 2006 8:01pm Biotech Teva and Eisai have called it quits on a pact to sell Azilect for Parkinson's in the U.S. Teva will take over full responsibility for the promotional work. Teva plans a launch at the end of July. Report Biotech
